End-stage renal disease incidence plateaus for now - Managed Care magazine PDF Print

The Evolving Biosimilars’ Landscape

Explore the complexities of the biosimilars’ landscape, such as naming, interchangeability and substitution, differences in the manufacturing processes, as well as the approval pathways & FDA guidelines for biologics, including draft guidance on biosimilars.



Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.